Image via Wikipedia
Is there a future for stem cell therapies that don’t use embryonic stem cells? An international study involving EPFL has raised doubts, by showing that “reprogramming” adult stem cells leads to genetic aberrations.
It’s a discordant note in the symphony of good news that usually accompanies stem cell research announcements. Stem cells hold enormous promise in regenerative medicine, thanks to their ability to regenerate diseased or damaged tissues. They have made it possible to markedly improve the effectiveness of many medical treatments – muscle regeneration in cases of dystrophy, skin grafts for treating burn victims, and the
Your hair may seem unwilling to cooperate some mornings, but at the root of each strand is a tiny partnership of stem cells that work very well together to make hair happen. New research from The Rockefeller University has elucidated how these adult stem cells communicate with each other to make hair grow and give it pigment.
“Deciphering the mechanisms behind stem cell differentiation advances our understanding of how adult stem cells can be used to maintain tissue integrity and heal wounds,” says Chiung-Ying Chang, a graduate student in the Laboratory of Elaine Fuchs, Rebecca C. Lancefield Professor
Official opening of Scottish Centre for Regenerative Medicine and bio-incubator facility, Nine, marks milestone in the growth of Edinburgh BioQuarter.
Research into conditions such as multiple sclerosis and heart and liver disease will benefit from multi-million stem cell research and life sciences facilities due to be opened today (Monday, 28th May) by HRH, the Princess Royal.
The Princess Royal unveiled plaques this afternoon at the £54 million Scottish Centre for Regenerative Medicine (SCRM) and £24 million bio-incubator facility, Nine, in Edinburgh.
The University of Edinburgh’s Scottish Centre for Regenerative Medicine will carry out cutting-edge stem cell research to help find therapies for
Bioheart Inc, a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announces an update on the phase I safety trial using adipose derived cells.
Approximately four years ago in April, 2010, Bioheart initiated a study using adipose derived stem cells (AdipoCell(TM)) in congestive heart failure patients. In collaboration with the Regenerative Medicine Institute of Tijuana, Mexico, five congestive heart failure patients were successfully treated in the initial pilot trial at Hospital Angeles Tijuana. Patients underwent a mini-lipoaspiration procedure where 60ccs of fat were removed.
This fat was processed to obtain the stromal vascular fraction (SVF) which
Veterinarians in Wichita conducted the first phase of a stem cell trial today in Wichita. Their goal is to treat laminitis, a disease in horses hoofs. They will do this using stem cells taken from the horses using liposuction. Laminitis is painful and even crippling for horses.
“Those horses usually digress over time to the point where they finally lose their life,” Dr. Preston Hickman said.
The trial is 90 days. The ten horses participating will have 3 stem cell injections over the three months.